Journal of Stroke & Cerebrovascular Diseases
Volume 19, Issue 2 , Pages 130-137, March 2010

The Stroke Practice Improvement Network: A Quasiexperimental Trial of a Multifaceted Intervention to Improve Quality

  • Judith A. Hinchey, MD, MS

      Affiliations

    • Institute of Clinical Care Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusettsh
    • Corresponding Author InformationAddress correspondence to Judith A. Hinchey, MD, MS, Tufts Medical Center, Caritas St. Elizabeth's Medical Center, CCP 8, 736 Cambridge St, Boston, MA 02135.
  • ,
  • Timothy Shephard, PhD, RN

      Affiliations

    • Stroke System Consulting, Charlottesville, Virginia
  • ,
  • Sarah T. Tonn, MPH

      Affiliations

    • American Academy of Neurology, St. Paul, Minnesota
  • ,
  • Robin Ruthazer, MPH

      Affiliations

    • Institute of Clinical Care Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusettsh
  • ,
  • Richard C. Hermann, MD, MS

      Affiliations

    • Institute of Clinical Care Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusettsh
  • ,
  • Harry P. Selker, MD, MPH

      Affiliations

    • Institute of Clinical Care Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusettsh
  • ,
  • David M. Kent, MD, MS

      Affiliations

    • Institute of Clinical Care Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusettsh

Received 13 February 2009; received in revised form 24 March 2009; accepted 26 March 2009.

Objective

The aim of this project was to determine whether a tailored multifaceted intervention aimed at site-specific barriers is more effective than audit feedback alone for improving adherence to inhospital stroke performance measures (PMs): door to needle time of less than 1hour for tissue plasminogen activator, dysphagia screening, deep venous thrombosis prophylaxis, and warfarin treatment for atrial fibrillation.

Methods

Hospitals were paired on baseline adherence to dysphagia screening and quality improvement infrastructure and randomized to receive audit feedback alone (n=7) versus audit feedback plus site-specific interventions (n=6). Data were collected on all admitted patients with stroke seen in the neurology department before and after a 6-month implementation period. The primary end point was the difference in postintervention adherence rates for each PM, except tissue plasminogen activator because of low sample size.

Results

Data were collected on 2071 preintervention patients and 1240 postintervention patients. Targeted site-specific interventions, such as standing orders and standardized dysphagia screens, were imperfectly implemented during the 6-month intervention period. For atrial fibrillation, the intervention group had an 11% higher postintervention adherence rate beyond that of the control group (98% v 87%, P < .005). No other statistically significant changes in PM adherence were observed.

Conclusion

Implementation of site-specific interventions for quality improvement of specific measures in stroke was difficult to achieve in a 6-month time frame and led to improved adherence for only one of 3 PMs. Studies with a longer intervention period and more sites are required to determine whether tailored interventions can enhance stroke improvement.

Key Words: Acute stroke, quality improvement, performance measures, evidence medicine, diffusion of medical innovation

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by grant number National Institute of Health K23NS002163, the American Academy of Neurology (AAN), the American Heart Association/American Stroke Association (AHA/ASA), and an unrestricted educational grant from Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut. The content is solely the responsibility of the authors and does not represent any official views of the NIH, AAN, AHA/ASA, or Boehringer Ingelheim.

PII: S1052-3057(09)00072-X

doi:10.1016/j.jstrokecerebrovasdis.2009.03.016

Journal of Stroke & Cerebrovascular Diseases
Volume 19, Issue 2 , Pages 130-137, March 2010